

Paris & Toulouse, September 28th, 2015

Limited company (société anonyme) with a Management Board (directoire)
and a Supervisory Board (conseil de surveillance)
with share capital of €1,547,578.30
Registered Office: Prologue-Biotech, 516 Rue Pierre et Marie Curie, 31670 Labège, France
Toulouse Trade and Companies Register (RCS) B 439 489 022

Disclosure of the total number of voting rights and shares composing the share capital

Persuant to Article 223-16 of the General Regulation of the French Financial Markets Authority
(AMF – Autorité des Marchés Financiers)

As of August 31st, 2015

Total number of outstanding shares	15,475,783
Theoretical voting rights ⁽¹⁾	15,475,783

Shares without voting rights

Treasury registered shares ⁽²⁾	0
Treasury bearer shares ⁽³⁾	14,754
Others ⁽⁴⁾	0

Exercisable voting rights = (1) - [(2) + (3) + (4)]	15,461,029
--	------------

As of July 31st, 2015

Total number of outstanding shares	15,457,934
Theoretical voting rights ⁽¹⁾	15,457,934

Shares without voting rights

Treasury registered shares ⁽²⁾	0
Treasury bearer shares ⁽³⁾	12,344
Others ⁽⁴⁾	0

Exercisable voting rights = (1) - [(2) + (3) + (4)]	15,445,590
--	------------



About Genticel

Aiming to solve a public health issue.

Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001 (known in Europe as ProCervix), its first-in-class immunotherapeutic vaccine candidate. The company has already completed patient recruitment for the phase 2 clinical trial of GTL001 in Europe.

Offering a promising technological platform.

Genticel's versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel's second candidate, GTL002, is a multivalent HPV therapeutic vaccine designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.

Focusing on value creation.

Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addition to this attractive HPV product pipeline, Genticel's versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIIL), the world's largest producer of vaccine doses. This partnership could generate up to \$57 million in revenues for Genticel, before royalties on sales. It will enable SIIIL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.

For more information, visit us at www.genticel.com